US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

OPUS GENETICS INC

1.40

+0.130010.24%

Volume:525.45K

Turnover:695.87K

Market Cap:83.87M

PE:-0.92

High:1.42

Open:1.32

Low:1.28

Close:1.27

52wk High:1.75

52wk Low:0.6500

Shares:59.91M

Float Shares:30.28M

Volume Ratio:1.76

T/O Rate:1.74%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.5143

EPS(LYR):-2.1535

ROE:-200.57%

ROA:-55.20%

PB:4.80

PE(LYR):-0.65

Loading ...

Overview Company News Filings

Opus Genetics Announces Dosing of First Patient in Phase 3 Trial of Phentolamine Ophthalmic Solution for Night Vision Disturbances

Opus Genetics Doses First Patient in Pivotal Lynx-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions

THOMSON REUTERS

Opus Genetics Inc. Set to Present Corporate Update at H.C. Wainwright 27th Annual Global Investment Conference

Press Release: Opus Genetics Appoints Rob Gagnon as Chief Financial Officer

Opus Genetics Announces One-Year Results of Phase I/II Study for OPGx-LCA5 Gene Therapy at International Symposium on Retinal Degeneration

BRIEF-Opus Genetics Inc Enters Agreements For Private Placement Of Shares

Opus Genetics Inc - Proceeds to Expedite Manufacturing for Gene Therapy Candidates - SEC Filing

THOMSON REUTERS

Opus Genetics Inc - Private Placement Gross Proceeds About $3.5 Mln - SEC Filing

THOMSON REUTERS

Opus Genetics Inc. Completes Private Placement, Issuing 3.1 Million Shares for $3.5 Million

Opus Genetics Secures FDA IND Clearance for OPGx-BEST1 Gene Therapy, Paving the Way for Phase 1/2 Trial Launch in 2025

Opus Genetics Inc - to Start Phase 1/2 Trial for Opgx-Best1 in 2H 2025

THOMSON REUTERS

Opus Genetics Announces FDA Clearance of Ind Application for Gene Therapy Candidate Opgx-Best1

THOMSON REUTERS

Opus Genetics Q2 EPS $(0.12) Beats $(0.20) Estimate, Sales $2.88M Miss $4.04M Estimate

Opus Genetics Q2 2025 Results: Reports Positive Clinical Milestones, No Sales/Revenue or Profit Data Provided

Opus Genetics - Expects Existing Cash Resources of $32.4 Mln to Fund Operations Into H2 2026

THOMSON REUTERS

Opus Genetics Inc - Opgx-Best1 Phase 1/2 Trial on Track for H2 2025

THOMSON REUTERS

Opus Genetics Inc: Q2 EPS $-0.12

THOMSON REUTERS

Opus Genetics Inc expected to post a loss of 20 cents a share - Earnings Preview

Opus Genetics Inc. to Participate in H.C. Wainwright Annual Ophthalmology Virtual Conference

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/IRD/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IRD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IRD\",,,,,undefined,":{"symbol":"IRD","market":"US","secType":"STK","nameCN":"OPUS GENETICS INC","latestPrice":1.4,"timestamp":1757361600000,"preClose":1.27,"halted":0,"volume":525446,"delay":0,"floatShares":30281341,"shares":59908055,"eps":-1.514273,"marketStatus":"Pre-Mkt","change":0.13,"latestTime":"09-09 06:56:31 EDT","open":1.32,"high":1.42,"low":1.28,"amount":695865.5300626,"amplitude":0.110236,"askPrice":1.51,"askSize":100,"bidPrice":1.19,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-1.514273,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1757424600000},"marketStatusCode":1,"adr":0,"listingDate":1100235600000,"exchange":"NASDAQ","adjPreClose":1.4,"postHourTrading":{"tag":"盘后","latestPrice":1.39,"preClose":1.4,"latestTime":"19:56 EDT","volume":15049,"amount":20648.8813,"timestamp":1757375768462},"volumeRatio":1.7568798354118178,"impliedVol":0.9026,"impliedVolPercentile":0.6728},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IRD\",,,,,undefined,":{"symbol":"IRD","floatShares":30281341,"roa":"-55.20%","roe":"-200.57%","lyrEps":-2.153504,"volumeRatio":1.7568798354118178,"shares":59908055,"dividePrice":0,"high":1.42,"amplitude":0.110236,"preClose":1.27,"low":1.28,"week52Low":0.65,"pbRate":"4.80","psRate":"5.44","week52High":1.75,"institutionHeld":0,"latestPrice":1.4,"committee":0.333333,"eps":-1.514273,"divideRate":0,"volume":525446,"delay":0,"ttmEps":-1.514273,"open":1.32,"prevYearClose":1.19,"prevWeekClose":1.27,"prevMonthClose":1.22,"prevQuarterClose":0.9421,"fiveDayClose":1.22,"twentyDayClose":1.07,"sixtyDayClose":0.9909},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IRD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-08-13","symbol":"IRD","fiscalQuarterEnding":"2025/06","expectedEps":-0.25,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1755057600000,"reportTimeType":"post","actualEps":-0.12},{"market":"US","date":"2025-05-15","symbol":"IRD","fiscalQuarterEnding":"2025/03","expectedEps":-0.34,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"pre","actualEps":-0.32},{"market":"US","date":"2025-03-31","symbol":"IRD","fiscalQuarterEnding":"2024/12","expectedEps":-0.34,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1743393600000,"reportTimeType":"pre","actualEps":-1.27},{"market":"US","date":"2024-11-12","symbol":"IRD","fiscalQuarterEnding":"2024/09","expectedEps":-0.3,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-0.29},{"market":"US","date":"2024-08-13","symbol":"IRD","fiscalQuarterEnding":"2024/06","expectedEps":-0.29,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1723521600000,"reportTimeType":"pre","actualEps":-0.3}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IRD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IRD\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":4,"updateTime":1750392000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/IRD\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"IRD","date":"2025-09-05","current":-1.384803,"percent":0.146226,"low":-2.964142,"twenty":-1.335088,"median":-1.160946,"eighty":-0.797415,"high":-0.560128,"avg":-1.196044,"sd":0.429084,"marketCap":80699383},"quantilePoints":[{"date":"2024-10-31","current":-2.785848,"twenty":-2.857166,"median":-2.64666,"eighty":-2.37374,"marketCap":39294383},{"date":"2024-11-08","current":-2.429259,"twenty":-2.692243,"median":-2.607554,"eighty":-2.476187,"marketCap":34264702},{"date":"2024-11-15","current":-1.225421,"twenty":-2.616468,"median":-2.568551,"eighty":-2.326813,"marketCap":33321637},{"date":"2024-11-22","current":-1.142487,"twenty":-2.607554,"median":-2.49612,"eighty":-1.192247,"marketCap":31066518},{"date":"2024-11-29","current":-1.288651,"twenty":-2.607554,"median":-2.173143,"eighty":-1.193702,"marketCap":35040987},{"date":"2024-12-06","current":-1.323479,"twenty":-2.603096,"median":-1.364112,"eighty":-1.225421,"marketCap":35988040},{"date":"2024-12-13","current":-1.288651,"twenty":-2.574123,"median":-1.335088,"eighty":-1.234669,"marketCap":35040987},{"date":"2024-12-20","current":-1.14597,"twenty":-2.527405,"median":-1.303163,"eighty":-1.16559,"marketCap":31161223},{"date":"2024-12-27","current":-1.253822,"twenty":-2.505202,"median":-1.288651,"eighty":-1.163268,"marketCap":34093933},{"date":"2025-01-03","current":-1.462793,"twenty":-2.49612,"median":-1.294455,"eighty":-1.172556,"marketCap":39776255},{"date":"2025-01-10","current":-1.683372,"twenty":-2.442631,"median":-1.320577,"eighty":-1.181843,"marketCap":45774262},{"date":"2025-01-17","current":-1.346698,"twenty":-2.224366,"median":-1.346698,"eighty":-1.20274,"marketCap":36619410},{"date":"2025-01-24","current":-1.335088,"twenty":-1.87928,"median":-1.335088,"eighty":-1.207384,"marketCap":36303725},{"date":"2025-01-31","current":-1.288651,"twenty":-1.676407,"median":-1.329284,"eighty":-1.218206,"marketCap":35040987},{"date":"2025-02-07","current":-1.416355,"twenty":-1.657832,"median":-1.323479,"eighty":-1.225421,"marketCap":38513517},{"date":"2025-02-14","current":-1.335088,"twenty":-1.648544,"median":-1.323479,"eighty":-1.239294,"marketCap":36303725},{"date":"2025-02-21","current":-1.288651,"twenty":-1.616038,"median":-1.323479,"eighty":-1.250654,"marketCap":35040987},{"date":"2025-02-28","current":-1.207384,"twenty":-1.525484,"median":-1.317674,"eighty":-1.232138,"marketCap":32831195},{"date":"2025-03-07","current":-1.160946,"twenty":-1.444218,"median":-1.31187,"eighty":-1.207384,"marketCap":31568457},{"date":"2025-03-14","current":-1.07968,"twenty":-1.411711,"median":-1.30026,"eighty":-1.1772,"marketCap":29358665},{"date":"2025-03-21","current":-1.335088,"twenty":-1.404745,"median":-1.30026,"eighty":-1.16559,"marketCap":36303725},{"date":"2025-03-28","current":-1.637559,"twenty":-1.525484,"median":-1.31187,"eighty":-1.1772,"marketCap":44528506},{"date":"2025-04-04","current":-0.76585,"twenty":-1.525484,"median":-1.306065,"eighty":-1.160946,"marketCap":44060874},{"date":"2025-04-11","current":-0.564318,"twenty":-1.462793,"median":-1.288651,"eighty":-1.14388,"marketCap":32466352},{"date":"2025-04-17","current":-0.581158,"twenty":-1.453505,"median":-1.288651,"eighty":-1.129154,"marketCap":33435158},{"date":"2025-04-25","current":-0.632466,"twenty":-1.414033,"median":-1.288651,"eighty":-1.081468,"marketCap":36387058},{"date":"2025-05-02","current":-0.741567,"twenty":-1.404745,"median":-1.288651,"eighty":-1.054291,"marketCap":42663825},{"date":"2025-05-09","current":-0.787263,"twenty":-1.404745,"median":-1.277041,"eighty":-0.791089,"marketCap":45292790},{"date":"2025-05-16","current":-0.737114,"twenty":-1.402423,"median":-1.253822,"eighty":-0.755291,"marketCap":43209631},{"date":"2025-05-23","current":-0.783669,"twenty":-1.393136,"median":-1.253822,"eighty":-0.759832,"marketCap":45938661},{"date":"2025-05-30","current":-0.771642,"twenty":-1.393136,"median":-1.251182,"eighty":-0.76585,"marketCap":45233661},{"date":"2025-06-06","current":-1.017762,"twenty":-1.393136,"median":-1.225421,"eighty":-0.767335,"marketCap":59661197},{"date":"2025-06-13","current":-1.009213,"twenty":-1.381526,"median":-1.207384,"eighty":-0.771254,"marketCap":59160042},{"date":"2025-06-20","current":-0.947842,"twenty":-1.372239,"median":-1.207384,"eighty":-0.771564,"marketCap":55562472},{"date":"2025-06-27","current":-1.038117,"twenty":-1.360629,"median":-1.184165,"eighty":-0.771642,"marketCap":60854420},{"date":"2025-07-03","current":-1.017762,"twenty":-1.358307,"median":-1.160946,"eighty":-0.77653,"marketCap":59661197},{"date":"2025-07-11","current":-1.139893,"twenty":-1.351342,"median":-1.160017,"eighty":-0.782117,"marketCap":66820540},{"date":"2025-07-18","current":-1.185692,"twenty":-1.346698,"median":-1.152239,"eighty":-0.783669,"marketCap":69505294},{"date":"2025-07-25","current":-1.231492,"twenty":-1.339732,"median":-1.160017,"eighty":-0.783669,"marketCap":72190048},{"date":"2025-08-01","current":-1.129716,"twenty":-1.335088,"median":-1.160248,"eighty":-0.785825,"marketCap":66223928},{"date":"2025-08-08","current":-1.10936,"twenty":-1.335088,"median":-1.151155,"eighty":-0.789762,"marketCap":65030704},{"date":"2025-08-15","current":-1.213067,"twenty":-1.335088,"median":-1.150071,"eighty":-0.791428,"marketCap":70691504},{"date":"2025-08-22","current":-1.177087,"twenty":-1.335088,"median":-1.151155,"eighty":-0.791428,"marketCap":68594722},{"date":"2025-08-29","current":-1.287434,"twenty":-1.335088,"median":-1.160248,"eighty":-0.791428,"marketCap":75025207},{"date":"2025-09-05","current":-1.384803,"twenty":-1.335088,"median":-1.160946,"eighty":-0.797415,"marketCap":80699383}],"updateTime":1757379447998},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IRD\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2564371785","title":"Opus Genetics Announces Dosing of First Patient in Phase 3 Trial of Phentolamine Ophthalmic Solution for Night Vision Disturbances","url":"https://stock-news.laohu8.com/highlight/detail?id=2564371785","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564371785?lang=en_us&edition=fundamental","pubTime":"2025-09-04 20:01","pubTimestamp":1756987268,"startTime":"0","endTime":"0","summary":"Opus Genetics Announces Dosing of First Patient in Phase 3 Trial of Phentolamine Ophthalmic Solution for Night Vision Disturbances. Opus Genetics Inc., a clinical-stage biopharmaceutical company, has announced the dosing of the first patient in its pivotal Phase 3 clinical trial, LYNX-3. The study is evaluating Phentolamine Ophthalmic Solution 0.75% for treating significant, chronic night driving impairment in keratorefractive patients with reduced mesopic vision. This trial follows the positive topline results of the earlier LYNX-2 Phase 3 trial announced in June 2025. The LYNX-3 study, which is the second Phase 3 trial for this indication, is being conducted with Fast Track designation and under a Special Protocol Assessment from the U.S. Food and Drug Administration. Results from this ongoing trial are yet to be presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely informa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250904:nNDLbCyNrr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IRD","LU0314104364.USD","NDAQ","BK4112","LU2095319765.USD","BK4585","IE00B3QW5Z07.USD","LU2210149790.SGD","BK4139","IE00B64PRP62.GBP","IE00BGHQF748.EUR","IE00BKPKM429.USD","BK4007","LU2210150020.SGD","BK4588"],"gpt_icon":0},{"id":"2564714533","title":"Opus Genetics Doses First Patient in Pivotal Lynx-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions","url":"https://stock-news.laohu8.com/highlight/detail?id=2564714533","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564714533?lang=en_us&edition=fundamental","pubTime":"2025-09-04 20:00","pubTimestamp":1756987203,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250904:nTUAVCN9R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","IRD","BK4139"],"gpt_icon":0},{"id":"2564984483","title":"Opus Genetics Inc. Set to Present Corporate Update at H.C. Wainwright 27th Annual Global Investment Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2564984483","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564984483?lang=en_us&edition=fundamental","pubTime":"2025-09-03 20:00","pubTimestamp":1756900813,"startTime":"0","endTime":"0","summary":"Opus Genetics Inc., a clinical-stage biopharmaceutical company, is set to participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025. During the event, CEO George Magrath and Chief Scientific and Development Officer Ash Jayagopal will deliver a corporate update. The presentation will be available on demand starting September 8, 2025, at 7:00 a.m. ET.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opus Genetics Inc. published the original content used to generate this news brief via GlobeNewswire  on September 03, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250903:nNDL6w5mrl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","BK4112","BK4588","NDAQ","IE00BKPKM429.USD","LU0314104364.USD","LU2210150020.SGD","LU2210149790.SGD","IRD","IE00BGHQF748.EUR","LU2095319765.USD","IE00B3QW5Z07.USD","BK4585","IE00B64PRP62.GBP"],"gpt_icon":0},{"id":"2564913804","title":"Press Release: Opus Genetics Appoints Rob Gagnon as Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2564913804","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564913804?lang=en_us&edition=fundamental","pubTime":"2025-09-02 20:00","pubTimestamp":1756814400,"startTime":"0","endTime":"0","summary":"RESEARCH TRIANGLE PARK, N.C., Sept. 02, 2025  -- Opus Genetics, Inc. , a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal diseases  and small molecule therapies for other ophthalmic disorders, today announced the appointment of Rob Gagnon, CPA, MBA, as Chief Financial Officer.Mr. Gagnon is an accomplished biotech executive with more than two decades of financial and operational leadership experience in both public and private companies. He has raised over $2 billion in capital, executed multiple strategic transactions, and held senior roles guiding companies through IPOs, late-stage clinical development, commercial launches, and M&A.Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases  and small molecule therapies for other ophthalmic disorders. The Company's pipeline features AAV-based gene therapies targeting inherited retinal diseases including Leber congenital am","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IRD","BK4007","BK4139","LCA"],"gpt_icon":0},{"id":"2562374525","title":"Opus Genetics Announces One-Year Results of Phase I/II Study for OPGx-LCA5 Gene Therapy at International Symposium on Retinal Degeneration","url":"https://stock-news.laohu8.com/highlight/detail?id=2562374525","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562374525?lang=en_us&edition=fundamental","pubTime":"2025-08-27 20:00","pubTimestamp":1756296041,"startTime":"0","endTime":"0","summary":"Opus Genetics Announces One-Year Results of Phase I/II Study for OPGx-LCA5 Gene Therapy at International Symposium on Retinal Degeneration. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opus Genetics Inc. published the original content used to generate this news brief via GlobeNewswire  on August 27, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250827:nNDLbNnqHH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","BK4585","IE00B3QW5Z07.USD","BK4588","LU2095319765.USD","IE00BKPKM429.USD","IE00BGHQF748.EUR","BK4007","IRD","LU2210149790.SGD","LU2210150020.SGD","BK4139","BK4112","LU0314104364.USD","NDAQ"],"gpt_icon":0},{"id":"2562273188","title":"BRIEF-Opus Genetics Inc Enters Agreements For Private Placement Of Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2562273188","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562273188?lang=en_us&edition=fundamental","pubTime":"2025-08-26 05:51","pubTimestamp":1756158706,"startTime":"0","endTime":"0","summary":"BRIEF-Opus Genetics Inc Enters Agreements For Private Placement Of Shares Aug 25  - Opus Genetics Inc IRD.O:OPUS GENETICS INC - ENTERS AGREEMENTS FOR PRIVATE PLACEMENT OF SHARES - SEC FILINGOPUS GENETICS INC - PRIVATE PLACEMENT GROSS PROCEEDS ABOUT $3.5 MILLION - SEC FILINGOPUS GENETICS INC - PROCEEDS TO EXPEDITE MANUFACTURING FOR GENE THERAPY CANDIDATES - SEC FILINGFurther company coverage: IRD.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250825:nFWN3UH0SF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","IRD","BK4139"],"gpt_icon":0},{"id":"2562787212","title":"Opus Genetics Inc - Proceeds to Expedite Manufacturing for Gene Therapy Candidates - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2562787212","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562787212?lang=en_us&edition=fundamental","pubTime":"2025-08-26 05:21","pubTimestamp":1756156870,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250825:nFWN3UH0SF:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","IRD","BK4139"],"gpt_icon":0},{"id":"2562278729","title":"Opus Genetics Inc - Private Placement Gross Proceeds About $3.5 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2562278729","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562278729?lang=en_us&edition=fundamental","pubTime":"2025-08-26 05:21","pubTimestamp":1756156870,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250825:nFWN3UH0SF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","IRD","BK4139"],"gpt_icon":0},{"id":"2562327875","title":"Opus Genetics Inc. Completes Private Placement, Issuing 3.1 Million Shares for $3.5 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2562327875","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562327875?lang=en_us&edition=fundamental","pubTime":"2025-08-26 05:20","pubTimestamp":1756156803,"startTime":"0","endTime":"0","summary":"Opus Genetics Inc. has completed a private placement transaction, issuing and selling a total of 3,138,338 shares of its common stock to certain investors for approximately $3.5 million. The transaction, which closed on August 25, 2025, was led by Cam Gallagher, Chair of the Company's board of directors, with an investment of $1.0 million, and included participation by Sean Ainsworth, the lead independent director, among other investors. The shares were sold under exemptions from registration provided by the Securities Act.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opus Genetics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250825:nNDL9sD1xh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IRD","BK4007","BK4139"],"gpt_icon":0},{"id":"2560902676","title":"Opus Genetics Secures FDA IND Clearance for OPGx-BEST1 Gene Therapy, Paving the Way for Phase 1/2 Trial Launch in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2560902676","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560902676?lang=en_us&edition=fundamental","pubTime":"2025-08-18 20:00","pubTimestamp":1755518427,"startTime":"0","endTime":"0","summary":"Opus Genetics Inc., a clinical-stage biopharmaceutical company specializing in gene therapies for inherited retinal diseases , announced that the U.S. Food and Drug Administration  has granted clearance for its Investigational New Drug  application for OPGx-BEST1. This gene therapy candidate is designed to treat bestrophin-1 -related IRD, a rare inherited retinal condition leading to progressive vision loss. With this IND clearance, Opus Genetics plans to commence a Phase 1/2 clinical trial in the latter half of 2025. The trial will evaluate the safety, tolerability, and preliminary efficacy of a single subretinal injection of OPGx-BEST1, marking a significant advancement for patients with no currently approved treatments.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as finan","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250818:nNDL3v6W38:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","BK4112","IRD","BK4007","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","LU2210149790.SGD","LU2210150020.SGD","BK4139","IE00BKPKM429.USD","BK4585","BK4588","LU2095319765.USD","IE00BGHQF748.EUR","NDAQ"],"gpt_icon":0},{"id":"2560902180","title":"Opus Genetics Inc - to Start Phase 1/2 Trial for Opgx-Best1 in 2H 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2560902180","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560902180?lang=en_us&edition=fundamental","pubTime":"2025-08-18 20:00","pubTimestamp":1755518402,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250818:nTUACTX2L:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IRD","BK4007"],"gpt_icon":0},{"id":"2560025179","title":"Opus Genetics Announces FDA Clearance of Ind Application for Gene Therapy Candidate Opgx-Best1","url":"https://stock-news.laohu8.com/highlight/detail?id=2560025179","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560025179?lang=en_us&edition=fundamental","pubTime":"2025-08-18 20:00","pubTimestamp":1755518402,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250818:nTUACTX2L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4139","IRD"],"gpt_icon":0},{"id":"2559981620","title":"Opus Genetics Q2 EPS $(0.12) Beats $(0.20) Estimate, Sales $2.88M Miss $4.04M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2559981620","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559981620?lang=en_us&edition=fundamental","pubTime":"2025-08-14 04:35","pubTimestamp":1755117338,"startTime":"0","endTime":"0","summary":"Opus Genetics (NASDAQ:IRD) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.20) by 41.46 percent.  The company reported quarterly sales of $2.88 million which missed the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/08/47107308/opus-genetics-q2-eps-0-12-beats-0-20-estimate-sales-2-88m-miss-4-04m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Opus Genetics Q2 EPS $(0.12) Beats $(0.20) Estimate, Sales $2.88M Miss $4.04M Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IRD"],"gpt_icon":0},{"id":"2559981216","title":"Opus Genetics Q2 2025 Results: Reports Positive Clinical Milestones, No Sales/Revenue or Profit Data Provided","url":"https://stock-news.laohu8.com/highlight/detail?id=2559981216","media":"Reuters","labels":["event","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559981216?lang=en_us&edition=fundamental","pubTime":"2025-08-14 04:30","pubTimestamp":1755117019,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opus Genetics Inc. published the original content used to generate this news brief via GlobeNewswire  on August 13, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250813:nNDL3WY7KF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"event,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","VTRS","IRD"],"gpt_icon":0},{"id":"2559426981","title":"Opus Genetics - Expects Existing Cash Resources of $32.4 Mln to Fund Operations Into H2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2559426981","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559426981?lang=en_us&edition=fundamental","pubTime":"2025-08-14 04:30","pubTimestamp":1755117003,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250813:nTUA6KYHVL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4007","IRD"],"gpt_icon":0},{"id":"2559237981","title":"Opus Genetics Inc - Opgx-Best1 Phase 1/2 Trial on Track for H2 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2559237981","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559237981?lang=en_us&edition=fundamental","pubTime":"2025-08-14 04:30","pubTimestamp":1755117003,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250813:nTUA6KYHVL:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IRD","BK4007","BK4139"],"gpt_icon":0},{"id":"2559098123","title":"Opus Genetics Inc: Q2 EPS $-0.12","url":"https://stock-news.laohu8.com/highlight/detail?id=2559098123","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559098123?lang=en_us&edition=fundamental","pubTime":"2025-08-14 04:30","pubTimestamp":1755117003,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250813:nTUA6KYHVL:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IRD","BK4007"],"gpt_icon":0},{"id":"2558579176","title":"Opus Genetics Inc  expected to post a loss of 20 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2558579176","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558579176?lang=en_us&edition=fundamental","pubTime":"2025-08-09 01:58","pubTimestamp":1754675894,"startTime":"0","endTime":"0","summary":"Opus Genetics Inc  expected to post a loss of20cents a share - Earnings Preview Opus Genetics Inc IRD.OQ IRD.O is expected to  show a rise in quarterly revenue when it reports  results on August 11 (e","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250808:nL8N3U037K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IRD"],"gpt_icon":0},{"id":"2557539133","title":"Opus Genetics Inc. to Participate in H.C. Wainwright Annual Ophthalmology Virtual Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2557539133","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557539133?lang=en_us&edition=fundamental","pubTime":"2025-08-05 20:00","pubTimestamp":1754395246,"startTime":"0","endTime":"0","summary":"Opus Genetics Inc., a clinical-stage biopharmaceutical company, announced that its CEO, Dr. George Magrath, will participate in a fireside chat at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference. The event will be available on demand on August 13, 2025, at 7:00 a.m. ET.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opus Genetics Inc. published the original content used to generate this news brief via GlobeNewswire  on August 05, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250805:nNDL4GX7Mw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00B64PRP62.GBP","LU2210150020.SGD","BK4112","IE00B3QW5Z07.USD","IRD","LU2210149790.SGD","NDAQ","IE00BGHQF748.EUR","BK4007","IE00BKPKM429.USD","LU0314104364.USD","LU2095319765.USD","BK4139","BK4588"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":59,"code":"91000000","status":"200"}]}}